Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRUSADE-1 bioequivalence study of crushed versus whole Epclusa
NL-OMON45504Phase 4Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Dec 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of velpatasvir and sofosbuvir in hepatitis C virus infection (2 arms), sponsored by Ziekenhuisapotheek. Primary endpoint: Bioequivalence of crushed versus whole sofosbuvir/velpatasvir. Started Dec 2017; status: active, not recruiting.
02
Drugs
velpatasvirsofosbuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON45504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45504.